Table 2.
Adverse events considered by the investigators to be related to saracatinib by grade according to National Cancer Institute Common Toxicity Criteria v3 (N=9)
| Grade, No. (%) |
|||
|---|---|---|---|
| Toxicity | 2 | 3 | 4 |
| Hypoxia | - | - | 1 (11) |
| AST | - | 2 (22) | - |
| Fatigue | - | 1 (11) | - |
| Lymphopenia | - | 1 (11) | - |
| Sodium, serum low | - | 1 (11) | - |
| Potassium, serum low | - | 1 (11) | - |
| Adrenal Insufficiency | 1 (11) | 1 (11) | - |
| Phosphate, serum low | 1 (11) | 1 (11) | - |
| Dyspnea | 1 (11) | - | - |
| Bilirubin | 1 (11) | - | - |
| ALT | 1 (11) | - | - |
| Glucose, serum high | 1 (11) | - | - |
| Hemoglobin | 1 (11) | - | - |
| Neutrophils/granulocytes | 1 (11) | - | - |